David J Jeffries
Overview
Explore the profile of David J Jeffries including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
818
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mackenzie G, Hill P, Jeffries D, Ndiaye M, Sahito S, Hossain I, et al.
Lancet Infect Dis
. 2021 Jul;
21(9):1293-1302.
PMID: 34280357
Background: The Gambia introduced seven-valent pneumococcal conjugate vaccine (PCV7) in August 2009, followed by PCV13 in May, 2011, using a schedule of three primary doses without a booster dose or...
2.
Mackenzie G, Hill P, Sahito S, Jeffries D, Hossain I, Bottomley C, et al.
Lancet Infect Dis
. 2017 Jun;
17(9):965-973.
PMID: 28601421
Background: Pneumococcal conjugate vaccines (PCVs) are used in many low-income countries but their impact on the incidence of pneumonia is unclear. The Gambia introduced PCV7 in August, 2009, and PCV13...
3.
Clarke E, Saidu Y, Adetifa J, Adigweme I, Badjie Hydara M, Bashorun A, et al.
Lancet Glob Health
. 2016 Jul;
4(8):e534-47.
PMID: 27364568
Background: The introduction of the inactivated poliovirus vaccine (IPV) represents a crucial step in the polio eradication endgame. This trial examined the safety and immunogenicity of IPV given alongside the...
4.
Mackenzie G, Hill P, Jeffries D, Hossain I, Uchendu U, Ameh D, et al.
Lancet Infect Dis
. 2016 Feb;
16(6):703-711.
PMID: 26897105
Background: Little information is available about the effect of pneumococcal conjugate vaccines (PCVs) in low-income countries. We measured the effect of these vaccines on invasive pneumococcal disease in The Gambia...
5.
Adetifa I, Ota M, Jeffries D, Lugos M, Hammond A, Battersby N, et al.
Am J Respir Crit Care Med
. 2012 Dec;
187(4):439-45.
PMID: 23220919
Rationale: Biomarkers that can be used to evaluate new interventions against latent tuberculosis infection (LTBI) and predict reactivation TB disease are urgently required. Objectives: To evaluate ESAT-6 and CFP-10 (EC)...
6.
Adetifa I, Ota M, Walther B, Hammond A, Lugos M, Jeffries D, et al.
PLoS One
. 2010 Sep;
5(9).
PMID: 20824136
Background: Qualitative and quantitative changes in IGRA response offer promise as biomarkers to monitor Tuberculosis (TB) drug therapy, and for the comparison of new interventions. We studied the decay kinetics...
7.
Sutherland J, de Jong B, Jeffries D, Adetifa I, Ota M
PLoS One
. 2010 Sep;
5(8):e12365.
PMID: 20811496
Background: Mycobacterium tuberculosis (MTb) infects approximately 2 billion people world-wide resulting in almost 2 million deaths per year. Determining biomarkers that distinguish different stages of tuberculosis (TB) infection and disease...
8.
Adetifa I, Ota M, Jeffries D, Hammond A, Lugos M, Donkor S, et al.
Pediatr Infect Dis J
. 2010 Jan;
29(5):439-43.
PMID: 20068506
Background: We compared the performance of tuberculin skin test (TST), Quantiferon-TB Gold in-tube (QFT-GIT), and T-SPOT.TB in diagnosing latent tuberculosis (LTBI) among childhood TB contacts in a TB endemic setting...
9.
Sutherland J, Jeffries D, Donkor S, Walther B, Hill P, Adetifa I, et al.
Tuberculosis (Edinb)
. 2009 Aug;
89(6):398-404.
PMID: 19683473
Most people infected with Mycobacterium tuberculosis, the causative agent of tuberculosis (TB) actually maintain a strong immune response and are able to control bacterial growth (deemed latently infected (LTBI)), while...
10.
Jeffries D, Abernethy N, de Jong B
BMC Bioinformatics
. 2009 Aug;
10:248.
PMID: 19674444
Background: Molecular genotyping of bacteria has revolutionized the study of tuberculosis epidemiology, yet these established laboratory techniques typically require subjective and laborious interpretation by trained professionals. In the context of...